Deal Watch: Beyond Pfizer/AstraZeneca, Plenty Of Fish In The Sea
Deals continue outside of the focus on Pfizer/AstraZeneca, with Novartis expanding its ophthalmology portfolio; Viking licensing five metabolic disease candidates from Ligand; BioAlliance and Topotarget moving closer to a merger creating a new orphan oncology firm to be called Onxeo; Ventrus and Assembly planning their own merger to focus on hepatitis B; and Daiichi Sankyo and Sanford-Burnham signing an R&D collaboration on novel cardiovascular and metabolic disease targets.
You may also be interested in...
The start-up is launching with a focus on metabolic and endocrine disorders through a deal with Ligand that will flesh out its pipeline and give it a major shareholder.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.